New medication, Istradefylline, gets approved for Parkinsonโ€™s disease

On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval...see more for Istradefylline, a new medication for Parkinsonโ€™s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA […]

Read More

$52 billion per year is spent on PD-related expenses, according to results of the Economic Burden of Parkinsonโ€™s Disease Study

$52 billion per year is spent on PD-related expenses, according to results of the Economic Burden of Parkinsonโ€™s Disease...see more Study In October 2018, APDA asked our constituents to consider participating in a new study called The Economic Burden of Parkinsonโ€™s Disease (PD), with the goal of estimating the economic burden of PD in the United […]

Read More

Recently published results of a GDNF intraputaminal infusion clinical trial

A clinical trial, is by definition an experiment or a test — an effort to determine if something works,...see more or doesnโ€™t.ย  Sometimes, although the intended outcome of a clinical trial may fall short of expectations, the results are nevertheless intriguing and may spark additional avenues of investigation. Such is the case in a clinical trial […]

Read More

FDA Approves Inbrijaโ„ขย (levodopa inhalation powder) Parkinsonโ€™s disease

FDA Approves Inbrijaโ„ขย (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJAโ„ข (levodopa inhalation powder)...see more for the treatment of OFF periods in people with Parkinsonโ€™s disease (PD) taking carbidopa/levodopa. INBRIJAโ„ข is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […]

Read More

FDA Approves Focused Ultrasound for Tremor-predominant Parkinsonโ€™s disease

FDA approves focused ultrasound for tremor-predominant Parkinsonโ€™s disease December 19, 2018 Tremor-predominant Parkinsonโ€™s disease (PD) joins Essential tremor (ET)...see more as an FDA-approved indication for the use of Focused ultrasound. Focused ultrasound is a technology in which beams of ultrasound waves are focused on a designated target thereby concentrating enough energy to create a small lesion. […]

Read More